Technical Articles

dendritic cell licensing
重组人cd40 fc蛋白：CD40 激动方向为什么在免疫肿瘤学里一直被寄予期待？
CD40 Agonism in Immuno-Oncology: Why Expectations Stay High
发布时间 2026-10-16
This article reviews CD40 agonism in immuno-oncology research: licensing dendritic cells, reversing the cold tumor phenotype, the safety trade-offs of systemic agonism and what standardized CD40 reagents contribute to preclinical workflows.
View details
  • Immunity/Inflamma
  • CD40 agonist
  • immuno-oncology
  • dendritic cell licensing
  • cold tumor
  • combination therapy
  • UA010194
Total 1
  • 1
Go to
UA
Link：
Products
Application
Cell FactorTarget Proteins
Custom Services
Custom Protein Expression ServicesCustom SPR Services
About Us
PromotionTechnical ArticlesProduct ApplicationFAQsCitationsCalculator ToolsAbout Us
We Media：
Facebook Linkedin YouTube X Thraeds Pinterest
©2021-2026 all rights reserved UNIV Biotechnology Co.,Ltd.
Privacy Policy
网站备案号 苏ICP备2025207586号-2 浙公网安备33010202004867号
 Business license (three certificates in one)
Tel：+86-25-56221161
E-mail：order@ua-bio.com
All products sold on this website shall not be used for clinical diagnosis or treatment of humans or animals, and shall only be used for non-medical purposes such as industrial or scientific research.